Inter-α-Trypsin Inhibitor Attenuates Complement Activation and Complement-Induced Lung Injury
- 15 September 2007
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 179 (6) , 4187-4192
Abstract
Complement activation is a central component of inflammation and sepsis and can lead to significant tissue injury. Complement factors are serum proteins that work through a cascade of proteolytic reactions to amplify proinflammatory signals. Inter-α-trypsin inhibitor (IaI) is an abundant serum protease inhibitor that contains potential complement-binding domains, and has been shown to improve survival in animal sepsis models. We hypothesized that IaI can bind complement and inhibit complement activation, thus ameliorating complement-dependent inflammation. We evaluated this hypothesis with in vitro complement activation assays and in vivo in a murine model of complement-dependent lung injury. We found that IaI inhibited complement activation through the classical and alternative pathways, inhibited complement-dependent phagocytosis in vitro, and reduced complement-dependent lung injury in vivo. This novel function of IaI provides a mechanistic explanation for its observed salutary effects in sepsis and opens new possibilities for its use as a treatment agent in inflammatory diseases.Keywords
This publication has 26 references indexed in Scilit:
- CD44 is a phagocytic receptorBlood, 2006
- Inter-Alpha-Inhibitor Proteins Are Endogenous Furin Inhibitors and Provide Protection against Experimental Anthrax IntoxicationInfection and Immunity, 2005
- Expression of functional recombinant von Willebrand factor-A domain from human complement C2: a potential binding site for C4 and CRITBiochemical Journal, 2005
- Bikunin Suppresses Lipopolysaccharide‐Induced Lethality through Down‐Regulation of Tumor Necrosis Factor–α and Interleukin‐1β in MacrophagesThe Journal of Infectious Diseases, 2005
- Delayed administration of human inter-α inhibitor proteins reduces mortality in sepsisCritical Care Medicine, 2004
- Correlation between Mortality and the Levels of Inter‐Alpha Inhibitors in the Plasma of Patients with Severe SepsisThe Journal of Infectious Diseases, 2003
- Molecular Heterogeneity of the SHAP-Hyaluronan ComplexJournal of Biological Chemistry, 2003
- Administration of human inter-α-inhibitors maintains hemodynamic stability and improves survival during sepsis*Critical Care Medicine, 2002
- Identification of the c3b binding site in a recombinant vWF-A domain of complement factor B by surface-enhanced laser desorption-ionisation affinity mass spectrometry and homology modelling: implications for the activity of factor BJournal of Molecular Biology, 1999
- Yeast Mannans inhibit binding and phagocytosis of zymosan by mouse peritoneal macrophagesJournal of Cell Biology, 1983